BEAM: Beam Therapeutics, Inc.
About
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Current Value
$30.561 Year Return
Current Value
$30.561 Year Return
Key Details
Market Cap
$2.50B
P/E Ratio
-17.16
1Y Stock Return
15.98%
1Y Revenue Growth
328.73%
Dividend Yield
0.00%
Price to Book
3.2
Strategies that include BEAM
Stock's related to BEAM
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRSP | 71.64% | $4.16B | -16.24% | 0.00% |
| NTLA | 67.02% | $1.50B | -47.71% | 0.00% |
| DNLI | 65.31% | $3.52B | +26.96% | 0.00% |
| RXRX | 60.32% | $2.90B | +0.27% | 0.00% |
| EDIT | 58.31% | $173.35M | -78.66% | 0.00% |
| DMRC | 56.18% | $774.20M | +6.71% | 0.00% |
| ABCL | 54.82% | $892.01M | -36.82% | 0.00% |
| KFRC | 52.99% | $1.16B | -4.23% | 1.24% |
| CRBU | 52.89% | $183.82M | -64.07% | 0.00% |
| CERS | 52.87% | $336.14M | +9.04% | 0.00% |
| SCL | 52.35% | $1.69B | -13.19% | 2.00% |
| PHR | 52.05% | $1.39B | +20.64% | 0.00% |
| PGEN | 51.50% | $228.76M | -30.88% | 0.00% |
| BLDP | 51.45% | $509.02M | -51.43% | 0.00% |
| TWST | 51.23% | $3.06B | +82.51% | 0.00% |
| ADPT | 51.18% | $990.26M | +53.20% | 0.00% |
| CWH | 51.12% | $1.50B | +4.32% | 1.98% |
| MCFT | 50.87% | $351.70M | +1.45% | 0.00% |
| ALLO | 50.62% | $459.18M | -7.20% | 0.00% |
| FATE | 50.42% | $259.68M | -5.00% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ADBE | -0.06% | $240.81B | -13.67% | 0.00% |
| VHC | -0.09% | $17.15M | -39.63% | 0.00% |
| FATBB | 0.12% | $78.36M | -13.14% | 12.28% |
| CRVO | 0.31% | $17.83M | -76.13% | 0.00% |
| AFL | 0.37% | $57.90B | +23.56% | 1.92% |
| CMG | 0.42% | $88.34B | +39.70% | 0.00% |
| KMB | -0.48% | $44.38B | +9.28% | 3.66% |
| PRPO | 0.52% | $8.76M | -5.79% | 0.00% |
| CAH | -0.71% | $29.14B | +11.57% | 1.66% |
| GIS | -0.72% | $36.72B | -0.90% | 3.60% |
| BACK | -0.73% | $2.07M | -23.57% | 0.00% |
| TPST | 0.75% | $38.66M | -74.17% | 0.00% |
| EQC | -0.76% | $164.22M | -92.06% | 0.00% |
| WRB | 0.79% | $23.36B | +28.48% | 0.69% |
| BSX | 0.83% | $132.94B | +61.22% | 0.00% |
| VSTA | -0.85% | $176.78M | -47.12% | 0.00% |
| MNR | 0.90% | $1.52B | -11.84% | 21.63% |
| TGS | 0.91% | $1.98B | +93.30% | 0.00% |
| EG | -0.94% | $15.58B | -8.50% | 2.14% |
| EDN | 0.95% | $1.01B | +132.45% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -13.43% | $74.13B | +26.36% | 0.46% |
| PGR | -13.16% | $144.85B | +49.74% | 0.46% |
| NERV | -11.90% | $16.36M | -63.15% | 0.00% |
| COR | -11.54% | $45.81B | +16.21% | 0.89% |
| CBOE | -11.42% | $21.25B | +13.78% | 1.16% |
| MNOV | -9.54% | $110.84M | +37.80% | 0.00% |
| HUSA | -9.48% | $16.88M | -24.12% | 0.00% |
| CYD | -9.03% | $370.18M | +10.76% | 4.19% |
| STG | -8.82% | $33.55M | -21.21% | 0.00% |
| GAN | -8.77% | $84.30M | +14.20% | 0.00% |
| ACGL | -8.41% | $35.12B | +22.28% | 0.00% |
| TCTM | -7.94% | $8.31M | -6.96% | 0.00% |
| PSQH | -7.72% | $179.82M | -14.26% | 0.00% |
| BTCT | -7.35% | $39.13M | +169.13% | 0.00% |
| CHD | -6.23% | $26.23B | +13.34% | 1.05% |
| NEUE | -6.17% | $43.41M | -19.51% | 0.00% |
| CME | -5.99% | $86.19B | +14.50% | 1.94% |
| OCX | -5.67% | $42.09M | -4.58% | 0.00% |
| PULM | -5.38% | $21.77M | +223.91% | 0.00% |
| NHTC | -5.19% | $54.23M | -15.29% | 17.09% |
ETF's related to BEAM
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -30.61% | $195.31M | 0.85% |
| USDU | -18.57% | $211.42M | 0.5% |
| TAIL | -17.78% | $68.43M | 0.59% |
| UUP | -16.76% | $386.70M | 0.77% |
| EQLS | -11.96% | $8.94M | 1% |
| CTA | -11.22% | $380.14M | 0.76% |
| KMLM | -8.94% | $332.27M | 0.9% |
| CORN | -8.51% | $61.14M | 0.2% |
| AGZD | -8.21% | $132.89M | 0.23% |
| DBA | -7.99% | $793.07M | 0.93% |
| KCCA | -7.73% | $123.70M | 0.87% |
| CLOI | -7.55% | $773.20M | 0.4% |
| WEAT | -7.48% | $122.96M | 0.28% |
| TBIL | -7.41% | $4.51B | 0.15% |
| MINT | -6.04% | $11.81B | 0.35% |
| BILZ | -5.43% | $558.25M | 0.14% |
| BIL | -4.88% | $34.60B | 0.1356% |
| BSCO | -4.88% | $2.14B | 0.1% |
| HIGH | -2.13% | $298.33M | 0.52% |
| SGOV | -2.00% | $28.68B | 0.09% |
News
Yahoo
We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against other worst ARK stocks to buy according to short sellers. Cathie Wood of ARK Investment is one of Wall Street’s most well-known hedge […]
Yahoo
On Saturday, Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs). The data were featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. Consistent with Beam’s previously announced data, updated data from seven patients treated with investigational base-editing therapy BEAM-101 demonstrated robust and durable increases i
Yahoo
BEAM appoints Sravan K. Emany as its new chief financial officer, effective Dec. 19. Shares rise on this leadership transition.
Finnhub
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology Annual Meeting All Seven Patients...
Yahoo
NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing Well Tolerated Without Need for Supportive Care Beam on Track to Initiate Phase 1-enabling Studies by End of 2024 Beam to Host Investor Event on Dec. 8, 2024, at 8 p.m. PT SAN DIEGO, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision g
Yahoo
All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Post-BEAM-101 Treatment Initial Safety Profile Consistent with Busulfan Conditioning and Autologous Hematopoietic Stem Cell Transplantation All Seven Patients Dosed Achieved Target Cell Dose with One or Two Mobilization Cycles and Experienced Rapid Neutrophil and Platelet Engraftment Markers of Hemolysis Normalized or Improved in All Patients Beam
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.